Companies Tracon Pharmaceuticals, Inc.
Tracon Pharmaceuticals (TCON): executive pay, fiscal 2022
Free brief. Every figure links to the company’s own filing.
Tracon Pharmaceuticals, Inc. no longer files a proxy statement; its last pay data is FY2022.
CEO pay, last three years
- $2,059,112FY2021
- $1,264,851FY2022
CEO total pay was $1,264,851 in fiscal 2022, down from $2,059,112 in fiscal 2021.
FY2022: salary $608,022 · bonus $0 · stock awards $0 · option awards $461,153
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Charles Theuer | $608,022 | $0 | $0 | $461,153 | $182,407 | $0 | $13,269 | $1,264,851 |
| President and Chief Executive Officer | ||||||||
| Scott Brown | 353,600 | 84,864 | — | 139,216 | — | — | 13,180 | 590,860 |
| Chief Financial Officer | ||||||||
| Mark Wiggins | 337,267 | 0 | 0 | 139,216 | 0 | 0 | 18,771 | 495,254 |
| Former Chief Business Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Charles Theuer | $1,264,851 | $2,059,112 | — | ↓ −794,261 |
| Scott Brown | 590,860 | 835,526 | — | ↓ −244,666 |
| Mark Wiggins | 495,254 | 882,568 | — | ↓ −387,314 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation policies and decisions are focused on incentivizing management to achieve defined corporate goals that are strongly aligned with stockholders' interests. Compensation is designed to attract and retain talented and experienced executives to lead the Company successfully in a competitive environment.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2022
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Scott Brown | OPTION | 2022-01-28 | — | — | 80,000 | — | $139,216 |
| Charles Theuer | OPTION | 2022-01-28 | — | — | 265,000 | — | 461,153 |
| Mark Wiggins | OPTION | 2022-01-28 | — | — | 80,000 | — | 139,216 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Scott Brown | $0 | $0 | $139,216 | 0.0% |
| Charles Theuer | 0 | 0 | 461,153 | 0.0% |
| Mark Wiggins | 0 | 0 | 139,216 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Scott Brown | Option | 209 | 7.9 | — |
| Mark Wiggins | Option | 375 | 7.9 | — |
| Charles Theuer | Option | 959 | 7.9 | — |
| Mark Wiggins | Option | 5,959 | 4.02 | — |
| Scott Brown | Option | 5,959 | 4.02 | — |
| Mark Wiggins | Option | 28,646 | 9.14 | — |
| Scott Brown | Option | 28,646 | 9.14 | — |
| Charles Theuer | Option | 33,367 | 4.02 | — |
| Mark Wiggins | Option | 80,000 | 2.32 | — |
| Scott Brown | Option | 80,000 | 2.32 | — |
| Charles Theuer | Option | 93,750 | 9.14 | — |
| Charles Theuer | Option | 265,000 | 2.32 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William R. LaRueIndependent · Audit (Chair) · Compensation | $60,000 | — | $15,325 | — | — | $75,325 |
| Saundra PelletierIndependent · Audit · Nominating and Corporate Governance (Chair) | 55,000 | — | 15,325 | — | — | 70,325 |
| Martin A. MattinglyIndependent · Compensation (Chair) · Nominating and Corporate Governance | 53,750 | — | 15,325 | — | — | 69,075 |
| Stephen T. WorlandIndependent · Audit · Nominating and Corporate Governance | 51,250 | — | 15,325 | — | — | 66,575 |
| Carol Lam, J.DIndependent · Compensation | 45,000 | — | 15,325 | — | — | 60,325 |
| J. Rainer Twiford, J.D., Ph.DIndependent · Compensation | 45,000 | — | 15,325 | — | — | 60,325 |
| Lisa Johnson-Pratt, M.DIndependent · Nominating and Corporate Governance | 43,750 | — | 15,325 | — | — | 59,075 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 7,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $353,750 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $353,750 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Tracon Pharmaceuticals as a peer
Companies that benchmark against TCON
No companies currently name TCON as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Tracon Pharmaceuticals, Inc. | 2022 | Charles Theuer | $608,022 | $0 | $461,153 | $182,407 | $1,264,851 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (17 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Charles Theuer. DEF 14A, filed 2023-03-08. Section “Executive Compensation” · page 22. As printed: 1,264,851. View filing ↗
- Section 01, Scott Brown. DEF 14A, filed 2023-03-08. Section “Executive Compensation” · page 22. As printed: 590,860. View filing ↗
- Section 01, Mark Wiggins. DEF 14A, filed 2023-03-08. Section “Executive Compensation” · page 22. As printed: 495,254. View filing ↗
- Section 03, Scott Brown OPTION. DEF 14A, filed 2023-03-08. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Charles Theuer OPTION. DEF 14A, filed 2023-03-08. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Wiggins OPTION. DEF 14A, filed 2023-03-08. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, William R. LaRue. DEF 14A, filed 2023-03-08. Section “Director Compensation”. As printed: 75,325. View filing ↗
- Section 08, Saundra Pelletier. DEF 14A, filed 2023-03-08. Section “Director Compensation”. As printed: 70,325. View filing ↗
- Section 08, Martin A. Mattingly. DEF 14A, filed 2023-03-08. Section “Director Compensation”. As printed: 69,075. View filing ↗
- Section 08, Stephen T. Worland. DEF 14A, filed 2023-03-08. Section “Director Compensation”. As printed: 66,575. View filing ↗
- Section 08, Carol Lam, J.D. DEF 14A, filed 2023-03-08. Section “Director Compensation”. As printed: 60,325. View filing ↗
- Section 08, J. Rainer Twiford, J.D., Ph.D. DEF 14A, filed 2023-03-08. Section “Director Compensation”. As printed: 60,325. View filing ↗
- Section 08, Lisa Johnson-Pratt, M.D. DEF 14A, filed 2023-03-08. Section “Director Compensation”. As printed: 59,075. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 353,750 + equity 0 + all other 0 = 353,750, summed across the director compensation table rows.
- Tracon Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2023-03-08. CEO total compensation as printed in Tracon Pharmaceuticals, Inc.'s own proxy. As printed: 1,264,851. View filing ↗